Translational Pharmacology of CNS and Metabolic Disorders for Testing New Modality Therapies

DATE

August 29, 2023

TIME

8:00 a.m. PDT / 11:00 a.m. EDT / 16:00 BST / 17:00 CEST - Duration: 60 Minutes

Overview

Animal studies may provide a close approximation to humans when addressing the key challenge of clinical translatability. In the preclinical setting, new insights into disease models and mechanisms are crucial to efficacy studies. In this webinar, we will share our experiences and insights of the mechanistic aspects of preclinical pharmacology in the areas of neurodegenerative diseases, NASH, and metabolic disorders (involving PCSK9, in particular). Additional discussion will focus on how such insights are used in testing new modalities such as oligonucleotides and AAV that target the CNS or the liver.

Key Learning Objectives:

Review spontaneous Alzheimer-like dementia, diet-induced NASH and other metabolic diseases in small and large animals
Dive into the clinical relevance of NASH models and insight into hepatic fibrosis
Learn how PCSK9 expression levels and/or activity are affected under metabolic induction
See how these mechanistic insights can help in testing new modalities

Who Should Attend:

Project Managers in Drug Discovery
Program Leaders and Directors of Drug Discovery
Scientists in Drug Discovery, including Medicinal Chemists, In Vivo Biologists in Neurodegenerative Diseases and NASH and other Metabolic Diseases, Pharmacologists, etc.
Scientists who are interested in new modality therapies

Brought to you by:

Speakers

Deming Xu, Ph.D.
Chief Pharmacologist, Executive Director, Head of In Vivo Pharmacology,
WuXi AppTec Discovery Biology

Kelly McSweeney
Contributing Editor,
C&EN Media Group

Registration

Forwarded this event? Clear the form

Work Email Address*

Salutation

First Name*

Last Name*

Company*

Job Title*

Address 1

City

State*

Zip / Post Code

Country*

Business Phone

We would like to learn more about the types of small and large animal models available for efficacy studies targeting CNS and liver disorders.

Yes, we would like to learn more about the uses and challenges of new modalities (such as oligonucleotides and AAV vectors) for targeting CNS and liver diseases.

We are interested in studying disease mechanisms for Alzheimer’s-like dementia, NASH, and other metabolic diseases in preclinical pharmacology models.

I would like to receive more information on products and services from the American Chemical Society

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

View On Demand Webinars